Literature DB >> 34561716

Prevalence of high-grade dysplasia in cytology-negative, HPV-positive cervical cancer screening.

Stephanie M Peace1, Ashley J Jennings2.   

Abstract

PURPOSE: This study has two aims: determine the prevalence of CIN3 + in patients with discordant cotesting, defined as negative cytology and positive human papillomavirus (HPV) testing, and identify factors (including HPV strain) associated with CIN3 + , defined as cervical intraepithelial neoplasia (CIN) 3 or cancer within this population.
METHODS: We conducted a retrospective chart review of women age 30-65 with intact cervices who had discordant cotesting results between January 1, 2013 and September 1, 2018, at an academic medical center. We used the t test for continuous variables and the Chi-square test for categorical variables to compare women with and without CIN3 + . To identify factors associated with CIN3 + , we performed univariate and multivariate logistic regression.
RESULTS: The primary outcome was the prevalence of CIN3 + based on pathologic diagnosis following biopsy or excisional procedure. Among 375 patients with discordant co-testing, the mean age was 43.8 years, 58.4% were parous, and 84.8% were white. Overall, 43/375 (12.0%) had CIN3 + and 7/375 (1.9%) had AIS. On logistic regression, only parity ≥ 1 (p = 0.04, adjusted OR = 2.23, CI = 1.06-4.68) was significantly associated with CIN3 + . HPV-18 was less likely to be associated with CIN3 + (p = 0.02, adjusted OR 0.08, CI 0.01-0.65) but was present in 43% of AIS cases. HPV16 and other HR-HPV strains were highly associated with CIN3 + .
CONCLUSION: Women with discordant cotesting are at significant risk for CIN3 + . We recommend that biopsy be performed at the time of indicated colposcopy for all patients with discordant cotesting to assess for high-grade dysplasia.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Colposcopy; Cytology; Discordant cotesting; HPV; High-grade dysplasia

Mesh:

Year:  2021        PMID: 34561716      PMCID: PMC9584775          DOI: 10.1007/s00404-021-06208-2

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.493


  15 in total

1.  Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study.

Authors:  M H Stoler; M Schiffman
Journal:  JAMA       Date:  2001-03-21       Impact factor: 56.272

2.  Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.

Authors:  Mark Schiffman; Walter K Kinney; Li C Cheung; Julia C Gage; Barbara Fetterman; Nancy E Poitras; Thomas S Lorey; Nicolas Wentzensen; Brian Befano; John Schussler; Hormuzd A Katki; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2018-05-01       Impact factor: 13.506

3.  Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management.

Authors:  Philip E Castle; Shagufta Aslam; Catherine Behrens
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-09-01       Impact factor: 4.254

4.  Biopsy correlates of abnormal cervical cytology classified using the Bethesda system.

Authors:  L S Massad; Y C Collins; P M Meyer
Journal:  Gynecol Oncol       Date:  2001-09       Impact factor: 5.482

5.  Multiple biopsies and detection of cervical cancer precursors at colposcopy.

Authors:  Nicolas Wentzensen; Joan L Walker; Michael A Gold; Katie M Smith; Rosemary E Zuna; Cara Mathews; S Terence Dunn; Roy Zhang; Katherine Moxley; Erin Bishop; Meaghan Tenney; Elizabeth Nugent; Barry I Graubard; Sholom Wacholder; Mark Schiffman
Journal:  J Clin Oncol       Date:  2014-11-24       Impact factor: 44.544

6.  2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.

Authors:  Rebecca B Perkins; Richard S Guido; Philip E Castle; David Chelmow; Mark H Einstein; Francisco Garcia; Warner K Huh; Jane J Kim; Anna-Barbara Moscicki; Ritu Nayar; Mona Saraiya; George F Sawaya; Nicolas Wentzensen; Mark Schiffman
Journal:  J Low Genit Tract Dis       Date:  2020-04       Impact factor: 1.925

7.  Retrospective study of the influence of HPV persistence on outcomes among women with high-risk HPV infections and negative cytology.

Authors:  Giorgio Bogani; Francesca Taverna; Claudia Lombardo; Chiara Borghi; Fabio Martinelli; Mauro Signorelli; Umberto Leone Roberti Maggiore; Valentina Chiappa; Cono Scaffa; Antonino Ditto; Domenica Lorusso; Francesco Raspagliesi
Journal:  Int J Gynaecol Obstet       Date:  2017-04-27       Impact factor: 3.561

8.  Relevance of random biopsy at the transformation zone when colposcopy is negative.

Authors:  Warner K Huh; Mario Sideri; Mark Stoler; Guili Zhang; Robert Feldman; Catherine M Behrens
Journal:  Obstet Gynecol       Date:  2014-10       Impact factor: 7.661

9.  Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.

Authors:  Angela A Cleveland; Julia W Gargano; Ina U Park; Marie R Griffin; Linda M Niccolai; Melissa Powell; Nancy M Bennett; Kayla Saadeh; Manideepthi Pemmaraju; Kyle Higgins; Sara Ehlers; Mary Scahill; Michelle L Johnson Jones; Troy Querec; Lauri E Markowitz; Elizabeth R Unger
Journal:  Int J Cancer       Date:  2019-05-06       Impact factor: 7.316

Review 10.  Diagnosis and Management of Adenocarcinoma in Situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations.

Authors:  Deanna Teoh; Fernanda Musa; Ritu Salani; Warner Huh; Edward Jimenez
Journal:  Obstet Gynecol       Date:  2020-04       Impact factor: 7.623

View more
  2 in total

1.  Proposal for a descriptive and differentiated presentation of the longitudinal impact of the new organized cancer screening guideline and HPV vaccination in Germany.

Authors:  F Neis; B Holleczek; M Henes; I Juhasz-Böss; D Wallwiener; K J Neis
Journal:  Arch Gynecol Obstet       Date:  2022-09-02       Impact factor: 2.493

2.  Development and psychometric properties of the human papillomavirus-quality of life (HPV-QoL) questionnaire to assess the impact of HPV on women health-related-quality-of-life.

Authors:  Pluvio J Coronado; Carmen González-Granados; Mar Ramírez-Mena; Javier Calvo; María Fasero; Mónica Bellón; Javier F García-Santos; Javier Rejas-Gutiérrez
Journal:  Arch Gynecol Obstet       Date:  2022-05-13       Impact factor: 2.493

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.